Key Technology, a US manufacturer of process automation systems, has promoted Bret Larreau to the new position of manager of business development. He takes responsibility for building new business alliances and developing acquisition opportunities that will expand Key’s solutions within the pharmaceutical and food manufacturing industries.
Larreau has been with Key Technology for eight years and brings 25 years of automated food processing equipment experience to his position. Prior to this promotion, he was the product marketing manager responsible for Key’s optical sorters.
Before joining Key, he was a senior project manager for Integrated Packaging Systems and prior to that, he worked in engineering, manufacturing management, sales support management and product management for DSI/Stein, part of FMC FoodTech.
‘It’s exciting to make this shift, leveraging my experience in the industry and recent market development activities, to focus on finding new opportunities to improve customers’ operations and grow Key’s business,’ said Larreau.
‘We’ve the resources and the personnel to make new partnerships, acquisitions, and licensing a high priority, while continuing to work closely with existing partners on ongoing projects.’
Key Technology makes a promotion
Bret Larreau becomes manager of business development
You may also like
Manufacturing
Titan Enterprises develops PFAS-free material options for turbine flowmeters
Titan Enterprises is evaluating high-performance, PFAS-free polymers for its turbine flowmeter range, aiming to maintain accuracy, durability and reliability while preparing for evolving international regulations
Manufacturing
What makes a GMP quality system effective in day-to-day pharmaceutical manufacturing?
Your quality system may have a procedure for almost everything: reporting a deviation, reviewing a batch record, changing equipment settings and training the people who operate it. But having a procedure and getting a useful answer from it are two different things
Regulatory
Pheno Therapeutics secures two patents for neurological drug pipeline
The Edinburgh-based biotech has strengthened its intellectual property portfolio for two selective GPR17 antagonists, including its lead multiple sclerosis candidate, PTD802, which has US and UK regulatory clearance to enter clinical trials
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Manufacturing
Scaling complexity without losing control: how manufacturing processes are adapting to the next generation of medicines (part V)
As therapies grow more complex, manufacturers must build commercial-scale thinking into early development, focus on meaningful monitoring and favour simplicity to keep production predictable